Inovio Pharmaceuticals Inc (NYSEMKT:INO) raises $63 million, secures capital needs for near-term trial advancement and preparation to enter Phase lll studies. Inovio Pharmaceuticals Inc (NYSEMKT:INO) dropped -1.96 percent to $3.51 yesterday on volume of INO 6.88million shares. The intra-day range of the stock was $3.50 to $3.71. Inovio Pharmaceuticals Inc (NYSEMKT:INO) has a market capitalization of $795.32million.

After announcing two years ago that it would stop working on depression drug Serdaxin, Rexahn Pharmaceuticals Inc. (NYSEMKT:RNN) has since shifted its focus to the discovery and development of new drugs to treat cancer. Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN)’s stock on Mar 06, 2014 reported a decrease of -1.37% to the closing price of $1.44. Its fifty two weeks range is $0.28 -$1.85. The total market capitalization recorded $67.27billion. The overall volume in the last trading session was 7.89million shares. In its share capital, Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) has 130.47million outstanding shares.

In a recent SA article, Michael Webb claimed that the subconscious of FDA AdCom panel members reviewing MannKind Corporation (NASDAQ:MNKD)’s Afrezza could lead to it being rejected. MannKind Corporation (NASDAQ:MNKD) stock performance was -3.06% in last session and finished the day at $5.71. Traded volume was 8.10million shares in the last session and the average volume of the stock remained 7.13million shares. The beta of the stock remained 1.77. MannKind Corporation (NASDAQ:MNKD) insider ownership is 0.60%.

Peregrine Pharmaceuticals (NASDAQ:PPHM) was able to achieve a strong gain where the share prices soared more than 50 percent on Wednesday. On Wednesday, shares of Peregrine Pharmaceuticals (NASDAQ:PPHM) dropped -7.46% to close the day at $2.61. Company return on investment (ROI) is -126.10% and its monthly performance is recorded as 49.14%. Peregrine Pharmaceuticals (NASDAQ:PPHM) quarterly revenue growth is 94.78%.